[go: up one dir, main page]

WO2001074296A3 - Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists - Google Patents

Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists Download PDF

Info

Publication number
WO2001074296A3
WO2001074296A3 PCT/US2001/010504 US0110504W WO0174296A3 WO 2001074296 A3 WO2001074296 A3 WO 2001074296A3 US 0110504 W US0110504 W US 0110504W WO 0174296 A3 WO0174296 A3 WO 0174296A3
Authority
WO
WIPO (PCT)
Prior art keywords
growth factor
vascular endothelial
endothelial growth
factor receptor
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/010504
Other languages
French (fr)
Other versions
WO2001074296A2 (en
Inventor
Larry Witte
Shahin Rafii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cornell Research Foundation Inc
ImClone LLC
Original Assignee
Cornell Research Foundation Inc
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornell Research Foundation Inc, ImClone Systems Inc filed Critical Cornell Research Foundation Inc
Priority to IL15199201A priority Critical patent/IL151992A0/en
Priority to CA002404040A priority patent/CA2404040A1/en
Priority to AU2001249736A priority patent/AU2001249736A1/en
Priority to EP01922996A priority patent/EP1436000A2/en
Priority to KR1020027013022A priority patent/KR20020087453A/en
Priority to JP2001572042A priority patent/JP2004501070A/en
Priority to SK1530-2002A priority patent/SK15302002A3/en
Publication of WO2001074296A2 publication Critical patent/WO2001074296A2/en
Anticipated expiration legal-status Critical
Publication of WO2001074296A3 publication Critical patent/WO2001074296A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A method of inhibiting the growth of non-solid tumor cells that are stimulated by a ligand of vascular endothelial growth factor in human patients, comprising treating the human patients with an effective amount of a vascular endothelial growth factor receptor antagonist.
PCT/US2001/010504 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists Ceased WO2001074296A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
IL15199201A IL151992A0 (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
CA002404040A CA2404040A1 (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
AU2001249736A AU2001249736A1 (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
EP01922996A EP1436000A2 (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists
KR1020027013022A KR20020087453A (en) 2000-03-31 2001-03-30 Treatment of Non-Solid Mammalian Tumors with Vascular Endothelial Growth Factor Receptor Antagonists
JP2001572042A JP2004501070A (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonist
SK1530-2002A SK15302002A3 (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54077000A 2000-03-31 2000-03-31
US09/540,770 2000-03-31

Publications (2)

Publication Number Publication Date
WO2001074296A2 WO2001074296A2 (en) 2001-10-11
WO2001074296A3 true WO2001074296A3 (en) 2004-05-06

Family

ID=24156859

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/010504 Ceased WO2001074296A2 (en) 2000-03-31 2001-03-30 Treatment of non-solid mammalian tumors with vascular endothelial growth factor receptor antagonists

Country Status (10)

Country Link
EP (1) EP1436000A2 (en)
JP (1) JP2004501070A (en)
KR (1) KR20020087453A (en)
AU (1) AU2001249736A1 (en)
CA (1) CA2404040A1 (en)
CZ (1) CZ20023518A3 (en)
IL (1) IL151992A0 (en)
RU (1) RU2002129574A (en)
SK (1) SK15302002A3 (en)
WO (1) WO2001074296A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2302106T3 (en) 2000-09-11 2008-07-01 Novartis Vaccines And Diagnostics, Inc. PROCEDURE FOR PREPARATION OF BENCIMIDAZOL-2-IL QUINOLINE DERIVATIVES.
EP1343782B1 (en) 2000-12-21 2009-05-06 SmithKline Beecham Corporation Pyrimidineamines as angiogenesis modulators
CA2453474A1 (en) * 2001-07-13 2003-01-23 Imclone Systems Incorporated Vegfr-1 antibodies to treat breast cancer
CA2478169C (en) 2002-03-04 2013-04-16 Imclone Systems Incorporated Human antibodies specific to kdr and uses thereof
BR0313743A (en) 2002-08-23 2005-07-05 Chiron Corp Benzimidazole quinolinones and uses of these
US7825132B2 (en) * 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
JP2007504122A (en) 2003-08-29 2007-03-01 ファイザー・インク Thienopyridine-phenylacetamide and its derivatives useful as novel anti-angiogenic agents
AP2006003619A0 (en) 2003-12-23 2006-06-30 Pfizer Novel quinoline derivatives
BR112014010774A2 (en) 2011-11-02 2017-06-13 Apexigen Inc anti-kdr antibodies and methods of use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DEDOUSSIS GEORGE V Z ET AL: "Endogenous interleukin 6 conveys resistance to cis-diamminedichloroplatinum-mediated apoptosis of the K562 human leukemic cell line", EXPERIMENTAL CELL RESEARCH, vol. 249, no. 2, 15 June 1999 (1999-06-15), pages 269 - 278, XP002267631, ISSN: 0014-4827 *
DIAS S ET AL: "NEUTRALIZING MOAB TO VERGF RECEPTORS INHIBIT PROFIFERATION AND MIGRATION OF A SUDSET OF HUMAN LEUKEMIAS THROUGH INTERACTION WITH VERGFR-2(KDR) AND VEGFR-1(FLT-1)", BLOOD, W.B.SAUNDERS COMPAGNY, ORLANDO, FL, US, vol. 94, no. 10,SUPPL01PT01, 15 November 1999 (1999-11-15), pages 620A, XP001021704, ISSN: 0006-4971 *
KATOH O ET AL: "EXPRESSION OF THE VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) RECEPTOR GENE, KDR, IN HEMATOPOIETIC CELLS AND INHIBITORY EFFECT OF VEGF ON APOPTOTIC CELL DEATH CAUSED BY IONIZING RADIATION", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 55, 1 December 1995 (1995-12-01), pages 5687 - 5692, XP002915174, ISSN: 0008-5472 *
PREWETT MARIE ET AL: "Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors", CANCER RESEARCH, vol. 59, no. 20, 15 October 1999 (1999-10-15), pages 5209 - 5218, XP002248647, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
IL151992A0 (en) 2003-04-10
KR20020087453A (en) 2002-11-22
SK15302002A3 (en) 2004-06-08
WO2001074296A2 (en) 2001-10-11
CZ20023518A3 (en) 2004-04-14
EP1436000A2 (en) 2004-07-14
CA2404040A1 (en) 2001-10-11
RU2002129574A (en) 2004-04-20
AU2001249736A1 (en) 2001-10-15
JP2004501070A (en) 2004-01-15

Similar Documents

Publication Publication Date Title
HK1047236A1 (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
BG108214A (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO2003075841A3 (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
WO2005011734A3 (en) Composition of a vegf antagonist and an anti-proliferative agent and its use for the treatment of cancer
PL319586A1 (en) Tie-2 ligands, methods of obtaining them and their application
IL161746A0 (en) Closed automated system for tissue based therapy, dosing and administration using same
WO2002080754A3 (en) Methods for using annexin for detecting cell death in vivo and treating associated conditions
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2005123104A3 (en) Use of vegf inhibitors for the treatment of human cancer
WO2001082899A3 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2002087555A3 (en) Use of bisphosphonates in the treatment of bone metastasis associated with prostate cancer
WO2006034455A3 (en) Polipeptide compounds for inhibiting angiogenesis and tumor growth
MXPA00011248A (en) Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases.
WO2004043389A3 (en) Methods of treating cancer and related methods
CA2534816A1 (en) Systems and methods for treating human inflammatory and proliferative diseases and wounds, with fatty acid metabolism inhibitors and/or glycolytic inhibitors
DE69919787D1 (en) Multi-site, parameter-controlled, implantable pacemaker / defibrillator
SG144712A1 (en) Nordihydroguaiartic derivaties for use in treatment of tumors
ATE375795T1 (en) USE OF ET743 IN COMBINATION THERAPY WITH DEXAMETHASONE FOR THE TREATMENT OF CANCER
PL378369A1 (en) Method of treating nausea, vomiting, retching or any combination thereof
WO2001007028A3 (en) The use of retinoid receptor antagonists in the treatment of prostate carcinoma
AU2002241736A1 (en) Method for preventing or treating pain by administering an endothelin antagonist
WO2002076548A3 (en) Methods and apparatus for treating diseased tissue
ZA200306541B (en) Method and dosage form for treating tumors by the administration of tegafur, uracil, folinic acid, paclitaxel and carboplatin.
WO2002092016A3 (en) Therapeutic use of rank antagonists
HK1047707A1 (en) Use of (+)-tramadol, o-demethyltramadol or (+)-o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol or (+)-o-desmethyl-n-mono-desmethyl-tramadol for treating urinary incontinence

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2404040

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 151992

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 572042

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 521693

Country of ref document: NZ

Ref document number: 1020027013022

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001249736

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200208051

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PV2002-3518

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 15302002

Country of ref document: SK

ENP Entry into the national phase

Ref document number: 2002 2002129574

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2001922996

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020027013022

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2002-3518

Country of ref document: CZ

WWP Wipo information: published in national office

Ref document number: 2001922996

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001922996

Country of ref document: EP